Comparison of the performance of different HPV genotyping methods for detecting genital HPV types

Journal of Medical Virology

Volumn 80, Issue 7, 2008, Pages 1264-1274

  Klug, Stefanie J ^a   Molijn, Anco ^b   Schopp, Betti ^c   Holz, Barbara ^c   Iftner, Angelika ^c   Quint, Wim ^b   Snijders, Peter J F ^d   Petry, Karl Ulrich ^e   Kjær, Susanne Krüger ^f   Munk, Christian ^f   Iftner, Thomas ^c  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^b DDL DIAGNOSTIC LABORATORY   (Netherlands)

^c UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^d VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^e HANNOVER MEDICAL SCHOOL   (Germany)

^f DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

Author keywords

HPV; Sensitivity; Specificity; Test comparison

Indexed keywords

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER PATIENT; CONTROLLED STUDY; FEMALE; GENOTYPE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; PREVALENCE; SENSITIVITY ANALYSIS; TUMOR BIOPSY; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CYTOLOGY; VIRUS DETECTION; WART VIRUS;

CERVIX UTERI; FEMALE; GENOTYPE; HUMANS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; SENSITIVITY AND SPECIFICITY; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS;

HUMAN PAPILLOMAVIRUS;

EID: 43949085707     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.21191     Document Type: Article

References (28)

1. Bernard HU, Chan SY, Manos MM, Ong CK, Villa LL, Delius H, Peyton CL, Bauer HM, Wheeler CM. 1994. Identification and assessment of known and novel human papillomaviruses by polymerase chain reaction amplification, restriction fragment length polymorphisms, nucleotide sequence, and phylogenetic algorithms. J Infect Dis 170:1077-1085.
2. Bosch FX, Lorincz A, Munoz N, Meijer CJLM, Shah KV. 2002. The casual relation between human papillomavirus and cervical cancer. J Clin Pathol 55:244-265.
3. Bulk S, Berkhof J, Bulkmans NW, Zielinski GD, Rozendaal L, van Kemenade FJ, Snijders PJ, Meijer CJ. 2006. Preferential risk of HPV16 for squamous cell carcinoma and of HPV18 for adenocarcinoma of the cervix compared to women with normal cytology in The Netherlands. Br J Cancer 94:171-175.
4. Castellsague X, Diaz M, de Sanjose S, Munoz N, Herrero R, Franceschi S, Peeling RW, Ashley R, Smith JS, Snijders PJ, Meijer CJ, Bosch FX. 2006. Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: Implications for screening and prevention. J Natl Cancer Inst 98:303-315.
5. Castle PE, Solomon D, Schiffman M, Wheeler CM. 2005. Human papillomavirus type 16 infections and 2-year absolute risk of cervical precancer in women with equivocal or mild cytologic abnormalities. J Natl Cancer Inst 20:1066-1071.
6. Cogliano V, Baan R, Straif K, Grosse Y, Secretan B, El GF. 2005. Carcinogenicity of human papillomaviruses. Lancet Oncol 6:204.
7. Cuzick J, Clavel C, Petry KU, Meijer CJ, Hoyer H, Ratnam S, Szarewski A, Birembaut P, Kulasingam S, Sasieni P, Iftner T. 2006. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer 119:1095-1101.
8. Gravitt PE, Peyton CL, Alessi TQ, Wheeler CM, Coutlee F, Hildesheim A, Schiffman MH, Scott DR, Apple RJ. 2000. Improved amplification of genital human papillomaviruses. J Clin Microbiol 38:357-361.
9. Herrero R, Castle PE, Schiffman M, Bratti MC, Hildesheim A, Morales J, Alfaro M, Sherman ME, Wacholder S, Chen S, Rodriguez AC, Burk RD. 2005. Epidemiologic profile of type-specific human papillomavirus infection and cervical neoplasia in Guanacaste. Costa Rica J Infect Dis 191:1796-1807.
10. Ho GY, Burk RD, Klein S, Kadish AS, Chang CJ, Palan P, Basu J, Tachezy R, Lewis R, Romney S. 1995. Persistent genital human papillomavirus infection as a risk factor for persistent cervical dysplasia. J Natl Cancer Inst 87:1365-1371.
11. Hwang TS, Jeong JK, Park M, Han HS, Choi HK, Park TS. 2003. Detection and typing of HPV genotypes in various cervical lesions by HPV oligonucleotide microarray. Gynecol Oncol Jul; 90:51-56.
12. Iftner A, Klug SJ, Garbe C, Blum A, Stancu A, Wilczynski SP, Iftner T. 2003. The prevalence of human papillomavirus genotypes in nonmelanoma skin cancers of nonimmunosuppressed individuals identifies high-risk genital types as possible risk factors. Cancer Res 63:7515-7519.
13. Jacobs MV, Snijders PJ, van den Brule AJ, Helmerhorst TJ, Meijer CJ, Walboomers JM. 1997. A general primer GP5+/GP6(+)-mediated PCR-enzyme immunoassay method for rapid detection of 14 high-risk and 6 low-risk human papillomavirus genotypes in cervical scrapings. J Clin Microbiol 35:791-795.
14. Khan MJ, Castle PE, Lorincz AT, Wacholder S, Sherman M, Scott DR, Rush BB, Glass AG, Schiffman M. 2005. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst 20:1072-1079.
15. Kjaer SK, Chackerian B, van den Brule AJ, Svare EI, Pauli G, Walbomers JM, Schiller JT, Bock JE, Sherman ME, Lowy DR, Meijer CL. 2001. High-risk human papillomavirus is sexually transmitted: Evidence from a follow-up study of virgins starting sexual activity (intercourse). Cancer Epidemiol Biomarkers Prev 10:101-106.
16. Kjaer S, van den Brule AJC, Paull G, Svare EI, Sherman ME, Thomsen BL, Suntum M, Bock JE, Poll PA, Meijer CJLM. 2002. Type specific persistence of high risk human papillomavirus (HPV) as indicator of high grade cervical squamous intraepithelial lesions in young women: Population based prospective follow up study. BMJ 325:572-576.
17. Kjaer S, Hogdall E, Frederiksen K, Munk C, van den Brule A, Svare E, Meijer C, Lorincz A, Iftner T. 2006. The absolute risk of cervical abnormalities in high-risk human papillomavirus-positive, cytologically normal women over a 10-year period. Cancer Res 66:10630-10636.
18. Kleter B, van Doorn L-J, ter Schegget J, Schrauwen L, van Krimpen K, Burger M, ter Harmsel B, Quint W. 1998. Technical advance - Novel short-fragment RCR assay for highly sensitive broadspectrum detection of anogenital human papillomaviruses. Am J Pathol 153:1731-1739.
19. Kleter B, van Doorn LJ, Schrauwen L, Molijn A, Sastrowijoto S, Ter SJ, Lindeman J, ter HB, Burger M, Quint W. 1999. Development and clinical evaluation of a highly sensitive PCR-reverse hybridization line probe assay for detection and identification of anogenital human papillomavirus. J Clin Microbiol 37:2508-2517.
20. Manos MM, Ting Y, Wright DK, Lewis AJ, Broker TR, Wolinsky SM. 1989. The use of polymerase chain reaction amplification for the detection of genetial human papillomaviruses. Cancer Cells 7:209-214.
21. Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV, Snijders P, Meijer CJLM. 2003. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 348:518-527.
22. Petry K-U, Menton S, Menton M, van Loenen-Frosch F, de Carvalho Gomes H, Holz B, Schopp B, Garbrecht-Buettner S, Davies P, Boehmer G, van Den Akker E, Iftner T. 2003. Inclusion of HPV-testing in routine cervical cancer screening for women above 29 years in Germany: Results for 8466 patients. Br J Cancer 88:1570-1577.
23. Qu W, Jiang G, Cruz Y, Chang CJ, Ho GYF, Klein RS, Burk RD. 1997. PCR detection of human papillomavirus: Comparison between MY09/MY11 and GP5+/GP6+ primer systems. J Clin Microbiol 35:1304-1310.
24. Remmink AJ, Walboomers JM, Helmerhorst TJ, Voorhorst FJ, Rozendaal L, Risse EK, Meijer CJ, Kenemans P. 1995. The presence of persistent high-risk HPV genotypes in dysplastic cervical lesions is associated with progressive disease: Natural history up to 36 months. Int J Cancer 61:306-311.
25. van den Brule AJ, Pol R, Fransen-Daalmeijer N, Schouls LM, Meijer CJ, Snijders PJ. 2002. GP5+/6+ PCR followed by reverse line blot analysis enables rapid and high-throughput identification of human papillomavirus genotypes. J Clin Microbiol 40:779-787.
26. van Doorn LJ, Quint W, Kleter B, Molijn A, Colau B, Martin MT, Kravang I, Torrez-Martinez N, Peyton CL, Wheeler CM. 2002. Genotyping of human papillomavirus in liquid cytology cervical specimens by the PGMY line blot assay and the SPF(10) line probe assay. J Clin Microbiol 40:979-983.
27. Vizcaino AP, Moreno V, Bosch FX, Munoz N, Barros-Dios XM, Borras J, Parkin DM. 2000. International trends in incidence of cervicalcancer. II. Squamous cell carcinoma. Int J Cancer 86:429-435.
28. Xi LF, Carter JJ, Galloway DA, Kuypers J, Hughes JP, Lee S-K, Adam DE, Kiviat NB, Koutsky LA. 2002. Acquisition and natural history of human papillomavirus type 16 variant infection among a cohort study of female university students. Cancer Epidemiol Biomarkers Prev 11:343-351.